Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

Subvisible particle testing addresses regulatory limits for particulate matter in parenteral drugs, ophthalmic solutions, and lipid emulsions.

Analysts rate the stock a Buy, with a mean price target of $354.95—about 15% below Saia’s current share price of $415.46. That disconnect underscores the market’s challenge: Saia shares have surged ...

Analysts expect earnings of 84 cents a share on revenue of $5.52 billion for the quarter ended December 2025. That represents a sharp sequential increase from the 19 cents per share reported in the ...

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Industrial Radiography Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ...

Polymarket partners with Kaito AI to launch attention markets, letting users trade on social media mindshare and public sentiment trends.

Patterns created using advanced fault models provide higher test coverage, improved defect detection, and higher-yielding ...

A record-setting volume of the white stuff hit Milton in late January and has consistently kept snow removal crews busy and ...

NordVPN Stopped Most Phishing Emails in Third-Party Testing, Study Says ...

WAKAYAMA -- With the Feb. 8 House of Representatives election approaching, campaigns across Japan are heating up. Campaign ...

We've tried to keep things reasonably upbeat this time around, in a bid to stop those SAD symptoms from surfacing. So if ...